Robert J. Fox

22.9k total citations · 5 hit papers
310 papers, 12.8k citations indexed

About

Robert J. Fox is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Robert J. Fox has authored 310 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 203 papers in Pathology and Forensic Medicine, 58 papers in Neurology and 58 papers in Oncology. Recurrent topics in Robert J. Fox's work include Multiple Sclerosis Research Studies (198 papers), Polyomavirus and related diseases (50 papers) and Peripheral Neuropathies and Disorders (37 papers). Robert J. Fox is often cited by papers focused on Multiple Sclerosis Research Studies (198 papers), Polyomavirus and related diseases (50 papers) and Peripheral Neuropathies and Disorders (37 papers). Robert J. Fox collaborates with scholars based in United States, Canada and Germany. Robert J. Fox's co-authors include Daniel Ontaneda, Douglas L. Arnold, Amit Bar‐Or, Michael Panzara, Ansi Chang, Emmanuelle Waubant, Craig H. Smith, Sunil Agarwal, Neena Sarkar and Bruce D. Trapp and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Robert J. Fox

294 papers receiving 12.5k citations

Hit Papers

B-Cell Depletion with Rituximab in Relapsing–Remitting Mu... 2006 2026 2012 2019 2008 2012 2006 2021 2025 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
    2008 1.8k citations Douglas L. Arnold, Robert J. Fox et al. profile →
  2. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
    2012 1.0k citations Robert J. Fox et al. profile →
  3. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
    2006 647 citations Ranjan Dutta, Robert J. Fox et al. profile →
  4. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
    2021 181 citations Amber Salter, Robert J. Fox et al. profile →
  5. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
    2025 26 citations Robert J. Fox, Anthony Traboulsee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert J. Fox United States 54 7.9k 2.8k 2.6k 2.2k 2.2k 310 12.8k
Alasdair Coles United Kingdom 43 9.1k 1.1× 3.3k 1.2× 3.8k 1.5× 1.9k 0.9× 2.7k 1.2× 199 13.4k
Bruce Cree United States 61 8.3k 1.0× 3.5k 1.3× 2.7k 1.1× 3.2k 1.4× 1.8k 0.8× 279 13.0k
Olaf Stüve United States 57 6.4k 0.8× 2.6k 0.9× 3.3k 1.3× 1.9k 0.9× 2.4k 1.1× 251 11.5k
Gianluigi Mancardi Italy 60 5.2k 0.7× 3.2k 1.1× 2.4k 0.9× 2.6k 1.2× 1.7k 0.8× 320 14.3k
Elliot M. Frohman United States 61 8.1k 1.0× 3.2k 1.1× 2.3k 0.9× 1.8k 0.8× 1.5k 0.7× 248 14.5k
Bernard M.J. Uitdehaag Netherlands 68 12.1k 1.5× 4.1k 1.5× 2.3k 0.9× 2.5k 1.1× 2.3k 1.0× 457 18.7k
Finn Sellebjerg Denmark 54 6.0k 0.8× 2.5k 0.9× 3.4k 1.3× 1.7k 0.8× 2.5k 1.1× 315 10.3k
Stephen L. Hauser United States 70 8.4k 1.1× 2.8k 1.0× 5.9k 2.3× 3.6k 1.6× 2.4k 1.1× 275 16.9k
Peter Rieckmann Germany 64 6.8k 0.9× 2.9k 1.0× 3.1k 1.2× 2.2k 1.0× 2.4k 1.1× 266 13.1k
Fredrik Piehl Sweden 64 5.7k 0.7× 4.1k 1.5× 2.7k 1.0× 3.7k 1.7× 1.9k 0.9× 324 15.1k

Countries citing papers authored by Robert J. Fox

Since Specialization
Citations

This map shows the geographic impact of Robert J. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Fox more than expected).

Fields of papers citing papers by Robert J. Fox

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Fox. The network helps show where Robert J. Fox may publish in the future.

Co-authorship network of co-authors of Robert J. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Fox. A scholar is included among the top collaborators of Robert J. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Fox. Robert J. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kim, Minjun, Soo-Yeon Ji, Hyeong‐Geol Shin, et al.. (2025). In-vivo high-resolution χ-separation at 7T. NeuroImage. 308. 121060–121060.
2.
Salter, Amber, Samantha Lancia, Gary Cutter, Robert J. Fox, & Ruth Ann Marrie. (2025). Post-acute sequela of COVID-19 infection in individuals with multiple sclerosis. Multiple Sclerosis Journal. 31(3). 314–323. 2 indexed citations
3.
Leavitt, Victoria M., Robert J. Fox, Jop Mostert, et al.. (2025). Cognitive test performance and disease progression in primary and secondary progressive MS: An analysis of the SPRINT-MS study. Multiple Sclerosis Journal. 31(7). 866–876. 1 indexed citations
4.
Fox, Robert J., Stanley Cohan, Yang Mao‐Draayer, et al.. (2025). Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study. Multiple Sclerosis Journal. 31(6). 706–718.
5.
Oh, Jiwon, Robert J. Fox, Douglas L. Arnold, et al.. (2025). Tolebrutinib Phase 2b Long-Term Extension Study. PubMed. 1(3). 1 indexed citations
6.
Noaiseh, Ghaith, Jennifer K. King, Arun S. Varadhachary, et al.. (2024). Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology. Arthritis & Rheumatology. 77(4). 383–389.
7.
Lancia, Samantha, Ruth Ann Marrie, Gary Cutter, Robert J. Fox, & Amber Salter. (2024). Association of patient-reported cognitive impairment with quality of life and employment in multiple sclerosis. Multiple Sclerosis and Related Disorders. 87. 105675–105675.
8.
Marrie, Ruth Ann, Samantha Lancia, Gary Cutter, Robert J. Fox, & Amber Salter. (2024). Access to Care and Health-Related Quality of Life in Multiple Sclerosis. Neurology Clinical Practice. 14(6). e200338–e200338.
9.
Bhattacharyya, Pallab, Robert J. Fox, Ken Sakaie, et al.. (2023). Characterizing multiple sclerosis disease progression using a combined structural and functional connectivity metric. Magnetic Resonance Imaging. 103. 185–191. 2 indexed citations
10.
Tervonen, Tommi, et al.. (2023). Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment. Multiple Sclerosis Journal - Experimental Translational and Clinical. 9(1). 3090513570–3090513570. 4 indexed citations
11.
Johnson, Joshua K., Bo Hu, Quinn R. Pack, et al.. (2023). Assisted ambulation to improve health outcomes for older medical inpatients (AMBULATE): study protocol for a randomized controlled trial. Trials. 24(1). 471–471. 2 indexed citations
12.
Salter, Amber, Alexander Keenan, Hoa H. Le, et al.. (2023). Severity and worsening of fatigue among individuals with multiple sclerosis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 9(2). 3100530279–3100530279. 6 indexed citations
13.
Marrie, Ruth Ann, Leanne Kosowan, Gary Cutter, Robert J. Fox, & Amber Salter. (2022). Disparities in Telehealth Care in Multiple Sclerosis. Neurology Clinical Practice. 12(3). 223–233. 7 indexed citations
14.
Fox, Robert J., Tommi Tervonen, Anne Brooks, et al.. (2022). The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial. Multiple Sclerosis Journal. 29(3). 427–435. 2 indexed citations
15.
O’Mahony, Julia, et al.. (2022). Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis. Neurology. 99(14). e1538–e1548. 19 indexed citations
16.
Marrie, Ruth Ann, et al.. (2022). Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 8(2). 3090465267–3090465267. 8 indexed citations
17.
Salter, Amber, Gary Cutter, Ruth Ann Marrie, et al.. (2022). Sources of Cannabis Information and Medical Guidance for Neurologic Use. Neurology Clinical Practice. 12(2). 102–112. 6 indexed citations
18.
Marrie, Ruth Ann, Stella Leung, Gary Cutter, Robert J. Fox, & Amber Salter. (2021). Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. Multiple Sclerosis Journal. 27(11). 1781–1789. 6 indexed citations
19.
Newsome, Scott D., Anne H. Cross, Robert J. Fox, et al.. (2021). COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America. Neurology Neuroimmunology & Neuroinflammation. 8(5). 12 indexed citations
20.
Dutta, Ranjan, Kedar Mahajan, Kunio Nakamura, et al.. (2019). Comprehensive Autopsy Program for Individuals with Multiple Sclerosis. Journal of Visualized Experiments. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alasdair Coles Breakdown of academic impact, for papers by Bruce Cree Breakdown of academic impact, for papers by Olaf Stüve Breakdown of academic impact, for papers by Gianluigi Mancardi Breakdown of academic impact, for papers by Elliot M. Frohman Breakdown of academic impact, for papers by Bernard M.J. Uitdehaag Breakdown of academic impact, for papers by Finn Sellebjerg Breakdown of academic impact, for papers by Stephen L. Hauser Breakdown of academic impact, for papers by Peter Rieckmann Breakdown of academic impact, for papers by Fredrik Piehl
Rankless by CCL
2026